Genmab — Januar 2021
-
Stoxx: Europæisk healthcare rammer foreløbigt toppunkt: https://www.proinvestor.com/investornyt/671333/stoxx-europaeisk-healthcare-rammer-forelobigt-toppunkt
-
God morgen.
-
Asien: Gevinster bliver hevet i land i hele regionen - NYhttps ://www.proinvestor.com/investornyt/671342/asien-gevinster-bliver-hevet-i-land-i-hele-regionen-ny
-
Fredagens aviser med Novozymes, Novo Nordisk og Danske Bank
https://www.proinvestor.com/investornyt/671338/fredagens-aviser-med-novozymes-novo-nordisk-og-danske-bank -
Barclays løfter til 2800
-
Havde tidligere 2550
-
Og fortsat overvægt:-)
-
Belantamab Mafodotin to Treat Multiple Myeloma: A Comprehensive Review of Disease, Drug Efficacy and Side Effects https://www.mdpi.com/1718-7729/28/1/63/htm
-
"The most prominent adverse events include corneal toxicity, thrombocytopenia, and anemia associated with the MMAF payload. Specific prophylaxis or treatment guidelines for belamaf-related keratopathy are not known, as the underlying mechanism of this toxicity remains unclear. Corticosteroid eye drops were not found to reduce the frequency of keratopathy in clinical studies.
-
Current management strategies include mainly dose modifications (delays and reductions) to allow for the regeneration of corneal epithelial cells and PF lubricant drops. Other strategies include cooling eye masks or vasoconstrictors administered at the start of the infusion. However, the true benefit of these mitigation strategies remains unclear."
-
Nyt TA signal som indikere sivende trend mod de 2182. Tror dog ikke den kommer ret meget under 2470 https://nbg1.your-objectstorage.com/proinvestor-dev/forum/boards/90037_22_jan.PNG
-
Ellers kan du supplere din position i 2182
-
Ja jeg har ikke så meget forstand på det, men det forvirrer mig, at udmeldingerne er så forskellige, det ville være en hjælp, hvis der var tidsfaktor på, altså kort eller langsigtet forudsigelse. Jeg så at TA. iflg.dig StockBull "var i hus" for få dage siden! hvad skyldes ændringen?
-
Barcleys er jo 12 mdr mig bekendt. TA signalet er fra autochartist som ofte har ret med deres signaler. Derudover er det normalt Genmab laver en "retracement på 10-15% ca. 4 gange per år og der kan man optimere sin profit eksemplevis ved at handle lidt CFDer
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind